Apr. 25 at 5:32 PM
$NWBO - The “NWBO moving shares to the LSE” thesis is structurally flawed.
NWBO already has a secondary LSE line (0K95), but it’s just a low-liquidity mirror of the US OTC listing, not a primary market. Shares cannot be “moved” between exchanges, and there are zero regulatory filings (FCA, prospectus, RNS) indicating a listing transition.
The argument mixes real UK operational facts (MHRA, manufacturing) with incorrect assumptions about market structure. Drug approval progress has no direct connection to exchange migration.
If NWBO upgrades its listing, the most likely path is NASDAQ or dual listing, not shifting primary trading to London.
Bottom line: plausible narrative, but no evidence and several mechanical errors